Mounjaro Wegovy Weight Loss Weight Management

Jun 25, 2026
15 MIN READ

Mounjaro vs. Wegovy: Which is Best for Weight Loss?

Mounjaro and Wegovy represent two distinct approaches to GLP-1 therapy for weight management. Understanding their differences helps you choose the right medication for your body and goals.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 25, 2026
15 MIN READ

mounjaro vs. wegovy: which is best for weight loss? — PlexusDx GLP-1 education

Last reviewed: June 25, 2026

Last updated: June 25, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Two medications dominate conversations about prescription weight loss: Mounjaro (tirzepatide) and Wegovy (semaglutide). While both activate incretin pathways, they work through different mechanisms and produce distinct outcomes in clinical trials. Knowing how they compare helps you make an informed decision about which approach fits your needs.

How Tirzepatide and Semaglutide Work Differently

Semaglutide, the active compound in Wegovy, targets one receptor: GLP-1. This receptor slows stomach emptying, reduces hunger signals, and increases feelings of fullness. The medication mimics glucagon-like peptide-1, a natural hormone your body produces after eating.

Tirzepatide, found in Mounjaro, activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). By engaging both pathways, tirzepatide creates a dual mechanism that may produce greater appetite suppression and metabolic changes than single-receptor therapies. Clinical data suggests this dual-action approach leads to larger weight reductions in many patients.

The practical difference: Semaglutide offers proven, long-term safety data from decades of diabetes use. Tirzepatide represents a newer approach with more dramatic recent weight loss results, though fewer years of widespread clinical observation.

Weight Loss Results: Clinical Trial Comparison

Wegovy trials showed average weight loss of 15–18% of body weight over 68 weeks in people without diabetes. Participants receiving the highest dose lost an average of 22% of their starting weight. These results established semaglutide as a benchmark for GLP-1 effectiveness.

Mounjaro trials demonstrated larger reductions: participants lost 21–22% of body weight at standard doses, with some reaching 25% at the highest dose during the same timeframe. A head-to-head comparison published in 2023 found that tirzepatide produced numerically greater weight loss than semaglutide, though individual response varies significantly.

Individual genetics influence these outcomes. PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R and GIPR genes that affect receptor sensitivity, helping predict which dual-receptor or single-receptor approach may work better for your metabolism.

Side Effects and Tolerability Profiles

Both medications commonly cause nausea, particularly during dose escalation. Gastrointestinal effects—including constipation, diarrhea, and reduced appetite—reflect the intended mechanism but can be uncomfortable during adjustment. Nausea typically improves after 4–6 weeks as your body adapts.

Tirzepatide carries a slightly higher incidence of gastrointestinal side effects compared to semaglutide in clinical trials, though this difference narrows at lower doses. Serious risks are rare with both medications but include pancreatitis and gallbladder issues in susceptible individuals. Always disclose your full medical history to your provider.

Tolerability is personal: some patients thrive on tirzepatide while others prefer semaglutide's gentler profile. PlexusDx treatment protocols start conservatively and adjust based on your response, minimizing side effect intensity while maximizing therapeutic benefit.

Cost Comparison and PlexusDx Accessibility

Brand-name Mounjaro and Wegovy carry steep prices when obtained through traditional pharmacy channels—often $900–$1,500 monthly without insurance. Compounded versions from licensed 503A pharmacies offer the same active compounds at a fraction of the cost, with no insurance requirement or membership fees.

PlexusDx provides compounded tirzepatide injection starting at $249 per month and compounded semaglutide injection at $149 per month. Both formulations are HSA/FSA eligible, and pricing remains flat regardless of dose—your dose may need to go up, but your price won't. This pricing structure removes financial barriers to accessing proven weight loss therapy.

For patients exploring whether tirzepatide or semaglutide aligns better with their genetic predispositions, PlexusDx offers the Precision Peptide Genetic Test at $99 as an add-on after your first month of treatment. This test maps 14 pathways and 49 peptides to identify which receptor pathway your body responds to most effectively.

Choosing Between Tirzepatide and Semaglutide for Your Goals

Select tirzepatide if you seek maximum weight loss potential and tolerate gastrointestinal effects reasonably well. Tirzepatide's dual-receptor mechanism suits patients with metabolic syndrome, moderate-to-severe obesity, or previous semaglutide treatment without adequate response.

Choose semaglutide if you prefer a gentler entry into GLP-1 therapy, have a sensitive stomach, or respond well to single-receptor activation. Semaglutide's longer safety history and established dosing protocols appeal to many patients beginning their weight loss journey.

PlexusDx clinicians work with you to select the medication matching your medical history, weight loss target, and side effect tolerance. Starting conservatively and adjusting your dose ensures you experience maximum benefit with minimal discomfort. Many patients find their ideal medication within the first 4–8 weeks.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I switch from Wegovy to Mounjaro if semaglutide isn't working well enough?

Yes. Many patients transition to tirzepatide after reaching a plateau on semaglutide or experiencing insufficient weight loss. PlexusDx providers can guide a safe transition, typically spacing the medications appropriately to prevent overlapping effects. Some patients need only a dose adjustment rather than a complete medication switch.

What does the clinical evidence say about long-term weight loss with tirzepatide versus semaglutide?

The 68-week SURMOUNT trials showed tirzepatide produced 21–25% weight loss compared to semaglutide's 15–22% in STEP trials. However, both medications require ongoing use; weight typically returns within months of stopping. Long-term data beyond 2 years remains limited for tirzepatide, whereas semaglutide has stronger multi-year evidence.

How much does compounded tirzepatide cost at PlexusDx compared to brand Mounjaro?

PlexusDx compounded tirzepatide injection starts at $249 per month, compared to $900–$1,200+ for brand Mounjaro through traditional pharmacies. PlexusDx pricing remains flat across all dose levels, with no insurance requirement or hidden membership fees. All medications come from licensed 503A compounding pharmacies.

Are compounded semaglutide and tirzepatide as safe as the brand-name versions?

Compounded medications from licensed 503A pharmacies contain identical active pharmaceutical ingredients to brand versions, manufactured under strict quality standards. They carry the same safety profile and side effect potential. The difference is cost and accessibility, not safety or efficacy.

How can the Precision Peptide Genetic Test help me decide between tirzepatide and semaglutide?

PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R (semaglutide receptor) and GIPR (tirzepatide's second receptor) that influence how strongly your body responds to each medication. Testing after your first month reveals whether your genetic profile predicts better outcomes with single or dual-receptor therapy, personalizing your treatment plan.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves